Edges in Network
| Network | GSE5851_top8000 - GSE5851 - SiGN-BN NNSR |
| Network Description | Phase II exploratory pharmacogenomics study of cetuximab monotherapy in patients with advanced metastatic CRC |
| Node | FCGR3B |
| Upstream (Parents) |
|---|
| (<<) SELL → FCGR3B |
| (<<) EVI2B → FCGR3B |
| (<<) CXCR2 → FCGR3B |
| (<<) CSF3R → FCGR3B |
| (<<) MNDA → FCGR3B |
| Downstream (Children) |
|---|
| FCGR3B → APOBEC3A (>>) |
| FCGR3B → C1orf222 (>>) |
| FCGR3B → TAAR5 (>>) |
| FCGR3B → TRIM58 (>>) |
| FCGR3B → HBG2///HBG1 (>>) |
| FCGR3B → HBB (>>) |
| FCGR3B → S100A8 (>>) |
| FCGR3B → HBA2///HBA1 (>>) |
| FCGR3B → VNN2 (>>) |
| FCGR3B → ALAS2 (>>) |
| FCGR3B → FFAR2 (>>) |
| FCGR3B → CCR3 (>>) |
| FCGR3B → RNASE1 (>>) |
| FCGR3B → GPR109B (>>) |
| FCGR3B → EMR3 (>>) |
| FCGR3B → S100A12 (>>) |
| FCGR3B → KCNJ15 (>>) |
| FCGR3B → CRLF1 (>>) |
| FCGR3B → TNFRSF10C (>>) |
| FCGR3B → MYO3A (>>) |
| FCGR3B → S100A9 (>>) |
| FCGR3B → SELL (>>) |
| FCGR3B → CD1A (>>) |
| FCGR3B → FLT4 (>>) |
| FCGR3B → RGS3 (>>) |
| FCGR3B → RGS2 (>>) |
| FCGR3B → CXCR2 (>>) |
| FCGR3B → FPR2 (>>) |
| FCGR3B → CSF3R (>>) |
| FCGR3B → SIGLEC5 (>>) |
| FCGR3B → ZNF696 (>>) |
